Enzon Pharmaceuticals Inc. (ENZN) Stock News, Earnings & History

(NASDAQ:ENZN) Healthcare

Enjoy Interactive Tools and Indicators

52wk high: 7.47
52wk low: 2.94
EPS: 0.02
P/E: 211.33
Div Rate: N/A
Yield: N/A
Market Cap: 138.62M
Avg Vol (3m): 329,062

Latest Headlines

    No articles on Enzon Pharmaceuticals Inc. in the past week.

More Articles About ENZN →

Company On Twitter

Company Profile

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The Company has developed several products, including PEG-INTRON. Enzon's product-focused strategy includes a drug development program that leverages its PEG modification and single-chain antibody (SCA) technologies.


Investor Relations | Press Releases

Insider Trading Cheat Sheet

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEBUHN ROBERT Director Aug 14 Sale 6.58 5,820 38,308 98,115 Aug 15 11:53 AM
LEBUHN ROBERT Director Aug 10 Sale 6.58 1,933 12,720 103,935 Aug 13 11:56 AM
HEBARD GEORGE Interim PEO and Interim COO Jun 20 Buy 6.88 5,000 34,395 18,737 Jun 21 05:17 PM
Rackear Andrew D. VP and General Counsel Jun 05 Sale 6.81 1,614 10,983 56,720 Jun 06 07:44 PM
Conover Charles SVP, R&D Program Management Jun 05 Sale 6.78 25,000 169,500 57,213 Jun 06 07:42 PM
Yahoo, HV, Market Watch, The Wall St. Journal